"..and more obsessed with phantom risks and protecting their own bureaucratic control over health care".
Editorial focused on recent ruling with Flibanserin, but points apply to Amarin and entire bureaucratic, politicized culture at FDA
"Lost" your password after all this time posting (apparently) and then post wrong numbers (apparently). We're to believe you??
Vascepa has substantiated medical claims. Not "unapproved". In their expanded labeling they simply wish to indicate substantiate claims based on medical community studies. It's the FDA that is wasting our money by creating a huge bureaucratic maze, that only repsonds to political pressure. from BP donors and lobbyists and lawyers. Amrn is at fault for not making a huge contribution to the Clinton Foundation...that would fix this with the FDA pronto.
Yes it does (already has) bring more visibility to Amarin/Vascepa...and stokes interest with the MD's who may not be familiar with vascepa
Of course we know Forbes wouldn't be so crass as to defend their first amendment rights to market and sell magazines . Nah.
You're welcome. With analysts, always good to trust but verify. Oppenheimer
made a more significant err in their report last week, and had to retract /clarify 90 minutes later after AMRN Management called them on it.
Sun Trust referenced the 52 week CLOSING highs/lows. For AMRN, the current 52 week closing high is $2.90 on March 13, 2015